JP7114465B2 - 薬剤の細胞内送達のための化合物および組成物 - Google Patents

薬剤の細胞内送達のための化合物および組成物 Download PDF

Info

Publication number
JP7114465B2
JP7114465B2 JP2018532573A JP2018532573A JP7114465B2 JP 7114465 B2 JP7114465 B2 JP 7114465B2 JP 2018532573 A JP2018532573 A JP 2018532573A JP 2018532573 A JP2018532573 A JP 2018532573A JP 7114465 B2 JP7114465 B2 JP 7114465B2
Authority
JP
Japan
Prior art keywords
alkyl
certain embodiments
group
nanoparticle composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018532573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508371A5 (enExample
JP2019508371A (ja
Inventor
イー． ベネナート、ケリー
ブッチャー、ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7114465(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2019508371A publication Critical patent/JP2019508371A/ja
Publication of JP2019508371A5 publication Critical patent/JP2019508371A5/ja
Priority to JP2022119505A priority Critical patent/JP7367137B2/ja
Application granted granted Critical
Publication of JP7114465B2 publication Critical patent/JP7114465B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
JP2018532573A 2015-12-22 2016-12-22 薬剤の細胞内送達のための化合物および組成物 Active JP7114465B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022119505A JP7367137B2 (ja) 2015-12-22 2022-07-27 薬剤の細胞内送達のための化合物および組成物

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562271200P 2015-12-22 2015-12-22
US201562271179P 2015-12-22 2015-12-22
US201562271160P 2015-12-22 2015-12-22
US201562271146P 2015-12-22 2015-12-22
US201562271137P 2015-12-22 2015-12-22
US62/271,179 2015-12-22
US62/271,137 2015-12-22
US62/271,160 2015-12-22
US62/271,146 2015-12-22
US62/271,200 2015-12-22
US201662338474P 2016-05-18 2016-05-18
US62/338,474 2016-05-18
US201662413345P 2016-10-26 2016-10-26
US62/413,345 2016-10-26
PCT/US2016/068300 WO2017112865A1 (en) 2015-12-22 2016-12-22 Compounds and compositions for intracellular delivery of agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022119505A Division JP7367137B2 (ja) 2015-12-22 2022-07-27 薬剤の細胞内送達のための化合物および組成物

Publications (3)

Publication Number Publication Date
JP2019508371A JP2019508371A (ja) 2019-03-28
JP2019508371A5 JP2019508371A5 (enExample) 2020-02-06
JP7114465B2 true JP7114465B2 (ja) 2022-08-08

Family

ID=57944500

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018532573A Active JP7114465B2 (ja) 2015-12-22 2016-12-22 薬剤の細胞内送達のための化合物および組成物
JP2022119505A Active JP7367137B2 (ja) 2015-12-22 2022-07-27 薬剤の細胞内送達のための化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022119505A Active JP7367137B2 (ja) 2015-12-22 2022-07-27 薬剤の細胞内送達のための化合物および組成物

Country Status (16)

Country Link
US (3) US10799463B2 (enExample)
EP (2) EP3394030B2 (enExample)
JP (2) JP7114465B2 (enExample)
AU (2) AU2016377681B2 (enExample)
CA (1) CA3007297A1 (enExample)
CY (1) CY1125087T1 (enExample)
DK (1) DK3394030T3 (enExample)
ES (1) ES2913626T5 (enExample)
HR (1) HRP20220268T1 (enExample)
HU (1) HUE057877T2 (enExample)
LT (1) LT3394030T (enExample)
PL (1) PL3394030T3 (enExample)
RS (1) RS63051B1 (enExample)
SI (1) SI3394030T1 (enExample)
SM (1) SMT202200252T1 (enExample)
WO (1) WO2017112865A1 (enExample)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
MA58292B1 (fr) 2014-04-23 2025-01-31 Modernatx, Inc. Vaccins à base d'acide nucléique
WO2015199952A1 (en) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
PL3718565T3 (pl) 2015-10-22 2022-09-19 Modernatx, Inc. Szczepionki przeciwko wirusom układu oddechowego
IL286515B2 (en) 2015-10-28 2024-02-01 Acuitas Therapeutics Inc Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
EP3394030B2 (en) 2015-12-22 2025-02-12 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP4166666A1 (en) 2016-09-14 2023-04-19 ModernaTX, Inc. High purity rna compositions and methods for preparation thereof
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP7738979B2 (ja) 2016-11-10 2025-09-16 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
DK3596041T3 (da) 2017-03-15 2023-01-23 Modernatx Inc Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
SI3596042T1 (sl) 2017-03-15 2022-04-29 Modernatx, Inc. Kristalne oblike amino lipidov
WO2018170336A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
JP2020514370A (ja) 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036000A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
MX2020002501A (es) * 2017-09-08 2020-09-17 Generation Bio Co Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.
MA51306A (fr) 2017-12-20 2020-10-28 Translate Bio Inc Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
CN112292395A (zh) 2018-04-17 2021-01-29 库瑞瓦格股份公司 用于疫苗接种的新型rsv rna分子和组合物
MA52709A (fr) * 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
KR20210031932A (ko) 2018-07-13 2021-03-23 젠맵 에이/에스 Cd38 항체의 변이체 및 그의 용도
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
WO2020047061A1 (en) 2018-08-29 2020-03-05 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
JP7640452B2 (ja) 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US12329857B2 (en) 2018-09-21 2025-06-17 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
CA3114699A1 (en) 2018-10-09 2020-04-16 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
CN109265359B (zh) * 2018-10-22 2021-09-03 大连百傲化学股份有限公司 一种侧链型水溶性聚季铵盐及其制备方法
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
EP4427739A3 (en) * 2019-01-31 2024-10-16 ModernaTX, Inc. Methods of preparing lipid nanoparticles
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
KR20220024022A (ko) 2019-05-14 2022-03-03 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 방법
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
AU2020328855A1 (en) 2019-08-14 2022-03-03 CureVac SE RNA combinations and compositions with decreased immunostimulatory properties
KR20220101077A (ko) 2019-09-19 2022-07-19 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물
KR20220084366A (ko) * 2019-10-18 2022-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 CAR mRNA 전달을 위한 지질 나노입자 및 그것의 제형
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
KR20220133957A (ko) 2020-01-31 2022-10-05 모더나티엑스, 인크. 지질 나노입자의 제조 방법
EP3886897A1 (en) 2020-02-04 2021-10-06 CureVac AG Coronavirus vaccine
US11969480B2 (en) 2020-02-25 2024-04-30 Translate Bio, Inc. Processes of preparing mRNA-loaded lipid nanoparticles
JP7681617B2 (ja) 2020-04-09 2025-05-22 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質ナノ粒子組成物
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
JP2023522249A (ja) 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
KR20230030588A (ko) 2020-06-30 2023-03-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
CN116096702A (zh) 2020-07-16 2023-05-09 爱康泰生治疗公司 用于脂质纳米颗粒的阳离子脂质
CN111718361B (zh) * 2020-07-23 2022-04-05 南京工业大学 一种金属β-内酰胺酶抑制剂及其制备方法与应用
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
MX2023001567A (es) 2020-08-06 2023-06-28 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
EP4168391A1 (en) * 2020-08-20 2023-04-26 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
IL301890A (en) 2020-10-14 2023-06-01 George Mason Res Foundation Inc Ionizable lipids and methods of manufacture and use thereof
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US20240050378A1 (en) * 2020-12-02 2024-02-15 Merck Sharp & Dohme Llc Lipid nanoparticle compositions containing monoester cationic lipids
AR124267A1 (es) * 2020-12-09 2023-03-01 Genentech Inc Métodos de alto rendimiento para preparar nanopartículas lipídicas y sus usos
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
CN112641942B (zh) * 2020-12-25 2023-05-19 深圳大学 近红光控纳米气体诊疗剂及其制备方法和应用
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
CN116615472A (zh) 2021-01-14 2023-08-18 苏州艾博生物科技有限公司 聚合物缀合的脂质化合物和脂质纳米颗粒组合物
CA3200333A1 (en) * 2021-01-14 2022-07-21 Bo YING Lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022174079A1 (en) 2021-02-12 2022-08-18 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20250345524A1 (en) 2021-03-31 2025-11-13 CureVac SE Syringes containing pharmaceutical compositions comprising rna
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2022247755A1 (en) 2021-05-24 2022-12-01 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN119137109A (zh) * 2021-08-12 2024-12-13 生命技术公司 用于核酸递送的脂质
JP2024538489A (ja) 2021-09-03 2024-10-23 キュアバック エスイー 核酸を送達するための新規な脂質ナノ粒子
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
TW202328192A (zh) 2021-09-06 2023-07-16 荷蘭商珍美寶公司 能結合ｃｄ２７之抗體、彼之變異體及彼等之用途
JP2024535004A (ja) * 2021-09-10 2024-09-26 浙江吉量科技有限公司 イオン化可能な脂質その調製および遺伝子送達における使用
WO2023044333A1 (en) * 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4204391A4 (en) 2021-10-08 2025-01-01 Suzhou Abogen Biosciences Co., Ltd. LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CA3234153A1 (en) 2021-10-08 2023-04-13 David Satijn Antibodies binding to cd30 and cd3
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
US20250281583A1 (en) 2021-10-13 2025-09-11 Modernatx, Inc. Composition of mrna-encoded il15 fusion proteins and methods of use thereof
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023107400A1 (en) * 2021-12-06 2023-06-15 Ohio State Innovation Foundation Diamino lipid (dal) compounds and pharmaceutical compositions comprising an immunotherapeutic agent
AR127892A1 (es) 2021-12-10 2024-03-06 Modernatx Inc Compuestos y composiciones para la administración de agentes terapéuticos
EP4448485A2 (en) 2021-12-16 2024-10-23 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023114889A1 (en) 2021-12-16 2023-06-22 Modernatx, Inc. Processes for preparing lipid nanoparticles
AU2022422983A1 (en) 2021-12-23 2024-05-16 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023154818A1 (en) 2022-02-09 2023-08-17 Modernatx, Inc. Mucosal administration methods and formulations
KR102465349B1 (ko) * 2022-02-25 2022-11-11 주식회사 테르나테라퓨틱스 신규 이온화 지질 및 이를 포함하는 지질 나노입자
KR20240166554A (ko) * 2022-03-25 2024-11-26 세일 바이오메디슨스, 인크. 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
US20250214046A1 (en) 2022-04-01 2025-07-03 Modernatx, Inc. Cross mixers for lipid nanoparticle production, and methods of operating the same
US20230322689A1 (en) * 2022-04-08 2023-10-12 SunVax mRNA Therapeutics Inc. Ionizable lipid compounds and lipid nanoparticle compositions
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
KR20250028547A (ko) 2022-05-25 2025-02-28 큐어백 에스이 대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
TW202348600A (zh) * 2022-06-06 2023-12-16 大陸商上海藍鵲生物醫藥有限公司 含氮鏈狀化合物、製備方法、包含其的組成物和應用
WO2023246218A1 (zh) * 2022-06-20 2023-12-28 成都威斯津生物医药科技有限公司 用于核酸递送的可电离脂质及其组合物
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
KR20250075664A (ko) 2022-09-26 2025-05-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 바이러스 백신
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
US20240189243A1 (en) * 2022-11-14 2024-06-13 Industrial Technology Research Institute Lipid compound or a derivative thereof and pharmaceutical composition employing the same
CN118125994A (zh) * 2022-11-25 2024-06-04 艾斯拓康医药科技(北京)有限公司 可离子化脂质及其应用
WO2024123978A1 (en) 2022-12-08 2024-06-13 Modernatx, Inc. Ionizable lipids with malonate tails
EP4644552A1 (en) 2022-12-29 2025-11-05 Rinuagene Biotechnology Co., Ltd. Polynucleotide molecule for preventing or treating hpv infection-related diseases
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024197307A1 (en) 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024197310A1 (en) 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024197309A1 (en) 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
AR132668A1 (es) 2023-05-12 2025-07-16 Genmab As Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
CN119219539A (zh) * 2023-06-29 2024-12-31 艾斯拓康医药科技(北京)有限公司 可离子化脂质及其应用
WO2025003280A1 (en) 2023-06-30 2025-01-02 Genmab A/S Antibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025046121A1 (en) 2023-09-01 2025-03-06 Novoarc Gmbh Lipid nanoparticle with nucleic acid cargo and ionizable lipid
TW202525812A (zh) * 2023-10-24 2025-07-01 南韓商綠十字股份有限公司 可離子化脂質及其用途
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025140594A1 (zh) * 2023-12-29 2025-07-03 厦门赛诺邦格生物科技股份有限公司 一种含有多级叔胺的不对称阳离子脂质
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
CN119661389A (zh) * 2024-10-15 2025-03-21 山东大学 一种基于反式-1,4-环己烷二甲醇的可电离脂质、脂质纳米颗粒及其制备方法与应用
CN119528797B (zh) * 2025-01-13 2025-05-06 北京安龙生物医药有限公司 用于递送治疗的脂质化合物、寡核苷酸递送系统及其制备方法和应用
CN120842107A (zh) * 2025-09-24 2025-10-28 北京悦康科创医药科技股份有限公司 乙二胺结构类型脾靶向的阳离子脂质化合物、包含其的组合物及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508235A (ja) 2008-11-07 2012-04-05 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
US20120295832A1 (en) 2011-05-17 2012-11-22 Arrowhead Research Corporation Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds

Family Cites Families (366)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324182A (en) 1962-12-26 1967-06-06 Monsanto Res Corp Penta-alkyldialkylenetriamines
US3872171A (en) 1971-05-24 1975-03-18 Pfizer Polyamines as antiviral agents in animals
US3799876A (en) * 1970-12-11 1974-03-26 Texaco Inc Corrosion inhibiting lubrication method
US4125544A (en) 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
JP3250802B2 (ja) 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
FR2676072B1 (fr) 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
EP0625049A4 (en) 1992-01-23 1995-07-12 Vical Inc EX VIVO GENTRANSFER.
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP2292771A3 (en) 1997-09-19 2011-07-27 Life Technologies Corporation Sense mRNA therapy
US6673192B1 (en) 1997-09-25 2004-01-06 Loctite Corporation Multi-amine compound primers for bonding of polyolefins with cyanoacrylate adhesives
WO1999022009A1 (en) 1997-10-24 1999-05-06 Megabios Corporation Methods for preparing polynucleotide transfection complexes
US6310197B1 (en) 1997-11-12 2001-10-30 The Brigham And Women's Hospital, Inc. Translation enhancer element of the human amyloid precursor protein gene
WO1999026663A2 (en) 1997-11-20 1999-06-03 Vical, Inc. Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
GB9808268D0 (en) 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
JP2000169864A (ja) 1998-12-07 2000-06-20 New Japan Chem Co Ltd 模型エンジン用燃料組成物
EP1156781B1 (en) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
AU7725500A (en) 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
WO2001055371A1 (en) 2000-01-28 2001-08-02 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
CN100384480C (zh) 2001-05-30 2008-04-30 斯克里普斯研究学院 核酸传递系统
ES2340532T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo.
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
EP1485070A1 (en) 2002-03-13 2004-12-15 Novartis AG Pharmaceutical microparticles
RU2302865C2 (ru) 2002-04-04 2007-07-20 Коли Фармасьютикал Гмбх Иммуностимулирующие g, u-содержащие олигорибонуклеотиды
EP2823809B1 (en) 2002-06-28 2016-11-02 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2542099A1 (en) 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
MXPA06015234A (es) 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
ES2407979T3 (es) 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
CA2611944A1 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
AU2006283077B2 (en) 2005-08-24 2012-06-28 The Scripps Research Institute Translation Enhancer-Element dependent vector systems
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
US8728527B2 (en) 2006-07-24 2014-05-20 Luminus Biosciences, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
ES2611924T3 (es) 2006-10-03 2017-05-11 Arbutus Biopharma Corporation Formulaciones que contienen lípidos
US8313777B2 (en) 2006-10-05 2012-11-20 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008109712A2 (en) 2007-03-05 2008-09-12 Washington University Nanoparticle delivery systems for membrane-integrating peptides
CA2702305C (en) 2007-03-30 2015-07-21 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
WO2008127688A1 (en) 2007-04-13 2008-10-23 Hart Communication Foundation Synchronizing timeslots in a wireless communication protocol
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
AU2008247488B2 (en) 2007-05-04 2014-02-27 Marina Biotech, Inc. Amino acid lipids and uses thereof
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
BRPI0815725A2 (pt) 2007-08-23 2015-02-10 Novartis Ag Métodos para detecção de oligonucleotídeos
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
TW200927915A (en) 2007-10-25 2009-07-01 Croda Int Plc Laundry formulations and method of cleaning
CN103911378A (zh) 2007-12-11 2014-07-09 斯克利普斯研究所 涉及mRNA翻译增强因子的组合物和方法
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
HUE025027T2 (en) 2008-01-31 2016-07-28 Curevac Gmbh (NuGiXmGnNv) nucleic acids and derivatives of the formula as immunostimulants / adjuvants
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009129395A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009129385A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US8323686B2 (en) 2008-04-25 2012-12-04 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
JP6363320B2 (ja) 2008-06-16 2018-07-25 ファイザー・インク 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
PL2285350T3 (pl) 2008-06-16 2018-03-30 Pfizer Inc. Sposoby otrzymywania funkcjonalizowanych kopolimerów dwublokowych stanowiących środki kierujące do stosowania przy wytwarzaniu nanocząstek terapeutycznych
WO2010030739A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
ES2475065T3 (es) 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
ES2993911T3 (en) 2008-11-10 2025-01-13 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
CA2780482A1 (en) 2008-11-17 2010-05-10 Anil K. Sood Hdl particles for delivery of nucleic acids
WO2010060818A1 (de) 2008-11-25 2010-06-03 Basf Se Alkoxylierte oligo- oder polyamine als oxidationsstabilisatoren
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20140141089A1 (en) 2009-02-11 2014-05-22 Colorado School Of Mines Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same
AU2010226434A1 (en) 2009-03-20 2011-10-13 Egen, Inc. Polyamine derivatives
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
US8715736B2 (en) 2009-04-30 2014-05-06 Florida Agricultural And Mechanical University Nanoparticle formulations for skin delivery
CA2760776C (en) 2009-05-05 2019-07-09 Alnylam Pharmaceuticals, Inc. Lipid compositions for the delivery of therapeutic agents
WO2010129687A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc Methods of delivering oligonucleotides to immune cells
US9080186B2 (en) 2009-05-16 2015-07-14 Agave Pharma, Incorporated Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
DK3431076T3 (da) 2009-06-10 2021-12-20 Arbutus Biopharma Corp Forbedret lipidformulering
KR20120050429A (ko) 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011017548A1 (en) † 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8449916B1 (en) 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
PH12012500929A1 (en) 2009-11-12 2012-11-26 Kao Corp Method for producing olefins
SI3338765T1 (sl) 2009-12-01 2019-05-31 Translate Bio, Inc. Derivat steroida za dostavo MRNA pri humanih genetskih boleznih
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
BR112012016021A8 (pt) 2009-12-11 2018-06-12 Bind Biosciences Inc Formulações estáveis para liofilização de partículas terapêuticas
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
EP2558074B1 (en) 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
CN103002878B (zh) 2010-04-09 2015-07-01 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
EP2567951B1 (en) 2010-04-28 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
WO2011153120A1 (en) 2010-06-04 2011-12-08 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9066971B2 (en) 2010-07-01 2015-06-30 Postech Academy-Industry Foundation Method for treating and diagnosing cancer by using cell-derived microvesicles
HRP20161352T1 (hr) 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2590626B1 (en) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
WO2012009644A2 (en) 2010-07-16 2012-01-19 Arizona Board Of Regents Methods to identify synthetic and natural rna elements that enhance protein translation
AU2011285200B2 (en) 2010-07-30 2014-08-21 CureVac SE Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
EP2605816B1 (en) 2010-08-20 2019-01-23 University Of Washington Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
CA2809863A1 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
PL4066857T3 (pl) 2010-08-31 2023-03-20 Glaxosmithkline Biologicals Sa Pegylowane liposomy do dostarczania rna kodującego immunogen
SMT202300096T1 (it) 2010-08-31 2023-05-12 Glaxosmithkline Biologicals Sa Liposomi piccoli per la somministrazione di rna codificante un immunogeno
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP3943114B1 (en) 2010-09-20 2024-08-07 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
AU2011307277A1 (en) 2010-09-30 2013-03-07 Merck Sharp & Dohme Corp. Low molecular weight cationic lipids for oligonucleotide delivery
JP2013545727A (ja) 2010-10-21 2013-12-26 メルク・シャープ・アンド・ドーム・コーポレーション オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
ES2702428T3 (es) 2010-11-15 2019-02-28 Life Technologies Corp Reactivos de transfección que contienen amina y métodos para prepararlos y usarlos
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
CN102068701B (zh) 2011-01-18 2012-11-07 沈阳药科大学 可断裂peg脂质衍生物在制剂中的应用
JP2014505064A (ja) 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
CA2827118A1 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CN102204920B (zh) 2011-03-18 2013-03-20 海南本创医药科技有限公司 阿司匹林钠普伐他汀钠药物组合物固体制剂
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
WO2012142132A1 (en) 2011-04-11 2012-10-18 Life Technologies Corporation Polymer particles and methods of making and using same
WO2013158127A1 (en) 2012-04-16 2013-10-24 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
WO2012149376A2 (en) 2011-04-28 2012-11-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
WO2012149268A1 (en) 2011-04-29 2012-11-01 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
WO2012153338A2 (en) 2011-05-12 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
DK2714017T3 (en) 2011-06-02 2018-09-03 Univ California MEMBRANE-WRAPPED NANOPARTICLES AND METHOD OF USE
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery
CA2838063C (en) 2011-06-08 2023-07-11 Shire Human Genetic Therapies, Inc. Cleavable lipids
CN102813929B (zh) 2011-06-09 2014-04-09 沈阳药科大学 低浓度peg脂质衍生物及其应用
RU2606846C2 (ru) 2011-07-06 2017-01-10 Новартис Аг Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
BR112014004544A2 (pt) 2011-08-31 2017-04-04 Mallinckrodt Llc modificação com peg de nanopartículas com h-fosfonatos
TR201900264T4 (tr) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013072929A2 (en) 2011-09-23 2013-05-23 Indian Institute Of Technology Nanop article based cosmetic composition
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
CN104023711A (zh) 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
AU2012325997C1 (en) 2011-10-18 2018-07-05 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
KR20140097215A (ko) 2011-10-31 2014-08-06 말린크로트 엘엘씨 암 치료를 위한 조합 리포좀 조성물
DK2773326T3 (en) 2011-11-04 2019-04-15 Nitto Denko Corp PROCEDURE FOR STERILE PREPARATION OF LIPID NUCLEIC ACID PARTICLES
WO2013067537A1 (en) 2011-11-04 2013-05-10 Univertiy Of Notre Dame Du Lac Nanoparticle-based drug delivery
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
CA2854054C (en) 2011-12-02 2020-05-12 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013086354A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
JP6305343B2 (ja) 2011-12-07 2018-04-04 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
EP2787977A4 (en) 2011-12-09 2015-05-06 Univ California LIPOSOMAL ACTIVE INVERTING
WO2013089151A1 (ja) 2011-12-12 2013-06-20 協和発酵キリン株式会社 カチオン性脂質を含有するドラッグデリバリーシステムのための脂質ナノ粒子
EP2792368A4 (en) 2011-12-12 2015-09-30 Kyowa Hakko Kirin Co Ltd LIPID NANOPARTICLES WITH COMBINATIONS OF CATIONIC LIPIDES
EP2604253A1 (en) 2011-12-13 2013-06-19 Otto Glatter Water-in-oil emulsions and methods for their preparation
WO2013087083A1 (en) 2011-12-15 2013-06-20 Biontech Ag Particles comprising single stranded rna and double stranded rna for immunomodulation
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
KR102081560B1 (ko) 2012-02-09 2020-02-25 라이프 테크놀로지스 코포레이션 친수성 중합체성 입자 및 그의 제조 방법
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US20140037573A1 (en) 2012-02-22 2014-02-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20130243867A1 (en) 2012-02-23 2013-09-19 University Of South Florida (A Florida Non-Profit Corporation) Micelle compositions and methods for their use
AU2013222179B2 (en) 2012-02-24 2017-08-24 Arbutus Biopharma Corporat ion Trialkyl cationic lipids and methods of use thereof
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
JP6527331B2 (ja) 2012-03-16 2019-06-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 標的指向アミノ酸脂質
EP2830991A1 (en) 2012-03-26 2015-02-04 President and Fellows of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
SG11201405545XA (en) 2012-03-27 2014-11-27 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2013143698A1 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
SG10201607968WA (en) 2012-03-27 2016-12-29 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
WO2013148541A1 (en) 2012-03-27 2013-10-03 Merck Sharp & Dohme Corp. DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
ES2858523T3 (es) 2012-03-29 2021-09-30 Translate Bio Inc Nanopartículas neutras derivadas de lípidos
WO2013151650A1 (en) 2012-04-05 2013-10-10 University Of Florida Research Foundation, Inc. Neurophilic nanoparticles
PL2836234T3 (pl) 2012-04-12 2020-02-28 Yale University Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych
US9402816B2 (en) 2012-04-19 2016-08-02 Sima Therapeutics, Inc. Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
WO2013163234A1 (en) 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2013173693A1 (en) 2012-05-18 2013-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoparticles with enhanced entry into cancer cells
AU2013266236A1 (en) 2012-05-23 2014-12-18 The Ohio State University Lipid nanoparticle compositions and methods of making and methods of using the same
ES2719598T3 (es) 2012-05-25 2019-07-11 Curevac Ag Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
HK1208618A1 (en) 2012-06-08 2016-03-11 夏尔人类遗传性治疗公司 Pulmonary delivery of mrna to non-lung target cells
WO2013185116A1 (en) 2012-06-08 2013-12-12 Payne Joseph E Lipids for therapeutic agent delivery formulations
TW201726599A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
WO2014008334A1 (en) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
US9956291B2 (en) 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014026284A1 (en) 2012-08-14 2014-02-20 Froese Aaron Internal structured self assembling liposomes
JP2015524849A (ja) 2012-08-15 2015-08-27 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 神経変性疾患に対するエキソソームに基づく治療法
WO2014047649A1 (en) 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
CA2925687A1 (en) 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
US20150240295A1 (en) 2012-09-28 2015-08-27 Ionovation Gmbh Reactive, lipophilic nucleoside building blocks for the synthesis of hydrophobic nucleic acids
CN104812372A (zh) 2012-10-04 2015-07-29 约翰内斯堡金山大学 脂质体药物递送系统
WO2014071072A2 (en) 2012-11-02 2014-05-08 Pungente Michael D Novel cationic carotenoid-based lipids for cellular nucleic acid uptake
WO2014072997A1 (en) 2012-11-07 2014-05-15 Council Of Scientific & Industrial Research Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules
EP2929035A1 (en) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
JP6456305B2 (ja) 2013-02-22 2019-01-23 キュアバック アーゲー ワクチン接種とｐｄ−１経路の阻害との組み合わせ
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
CA2906732C (en) 2013-03-15 2023-08-08 The University Of British Columbia Lipid nanoparticles for transfection and related methods
EP3757570B1 (en) 2013-03-15 2023-10-11 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
AR096203A1 (es) 2013-05-06 2015-12-16 Alnylam Pharmaceuticals Inc Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
WO2015002667A1 (en) 2013-07-01 2015-01-08 Myq, Inc. A location regulated point-of-sale system and enhancements
CN105555757A (zh) 2013-07-23 2016-05-04 普洛体维生物治疗公司 用于递送信使rna的组合物和方法
MY174677A (en) 2013-08-21 2020-05-06 Curevac Ag Composition and vaccine for treating lung cancer
CA2915904A1 (en) 2013-08-21 2015-02-26 Curevac Ag Composition and vaccine for treating prostate cancer
RU2712743C2 (ru) 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства
RU2733424C2 (ru) 2013-08-21 2020-10-01 Куревак Аг Способ повышения экспрессии кодируемых рнк белков
MX369469B (es) 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
AU2014375404C1 (en) 2013-12-30 2020-11-19 CureVac Manufacturing GmbH Methods for RNA analysis
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
DK3090053T3 (en) 2013-12-30 2019-02-25 Curevac Ag Artificial nucleic acid molecules
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015154002A1 (en) 2014-04-04 2015-10-08 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
WO2015199952A1 (en) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
CN104644555A (zh) 2014-11-18 2015-05-27 中国科学院过程工程研究所 一种避免加速血液清除现象的长循环脂质体、制备方法及应用
CN107530436B (zh) 2015-01-21 2022-03-29 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
CA2984125A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
JP2018150239A (ja) * 2015-07-15 2018-09-27 協和発酵キリン株式会社 β２ＧＰＩ遺伝子発現抑制ＲＮＡｉ医薬組成物
EP3325505B1 (en) 2015-07-23 2020-08-19 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
JP2018531290A (ja) 2015-10-22 2018-10-25 モデルナティーエックス， インコーポレイテッド 性感染症ワクチン
PL3718565T3 (pl) 2015-10-22 2022-09-19 Modernatx, Inc. Szczepionki przeciwko wirusom układu oddechowego
IL286515B2 (en) 2015-10-28 2024-02-01 Acuitas Therapeutics Inc Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
SMT202200358T1 (it) 2015-12-10 2022-11-18 Modernatx Inc Composizioni e metodi di rilascio degli agenti terapeutici
WO2017100744A1 (en) * 2015-12-11 2017-06-15 Preceres Inc. Aminolipidoids and uses thereof
CA3007108A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3394030B2 (en) 2015-12-22 2025-02-12 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017176974A1 (en) 2016-04-06 2017-10-12 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017192470A1 (en) 2016-05-03 2017-11-09 Merck Sharp & Dohme Corp. Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides
MX393869B (es) 2016-05-18 2025-03-24 Modernatx Inc Polinucleotidos que codifican interleucina-12 (il12) y usos de los mismos.
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
EP3458104A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
EP3458105B1 (en) 2016-05-18 2024-01-17 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
AU2017268399B2 (en) 2016-05-18 2023-01-12 Modernatx, Inc. mRNA combination therapy for the treatment of cancer
US20190382774A1 (en) 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
WO2017201333A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
JP7194594B2 (ja) 2016-05-18 2022-12-22 モデルナティエックス インコーポレイテッド 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
MA45036A (fr) * 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2017201347A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
EP3896164A1 (en) 2016-05-18 2021-10-20 ModernaTX, Inc. Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
CA3027201A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US20200163878A1 (en) 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines
EP3532097A1 (en) 2016-10-27 2019-09-04 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
DK3596041T3 (da) 2017-03-15 2023-01-23 Modernatx Inc Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
SI3596042T1 (sl) 2017-03-15 2022-04-29 Modernatx, Inc. Kristalne oblike amino lipidov
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
WO2018225871A1 (ja) 2017-06-09 2018-12-13 協和発酵キリン株式会社 カチオン性脂質としての化合物
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3746052A1 (en) 2018-01-30 2020-12-09 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
CN112292395A (zh) 2018-04-17 2021-01-29 库瑞瓦格股份公司 用于疫苗接种的新型rsv rna分子和组合物
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
KR20220103923A (ko) 2019-09-19 2022-07-25 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 신규한 헤드기 지질 화합물 및 조성물
KR20220101077A (ko) 2019-09-19 2022-07-19 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물
JP7638973B2 (ja) 2019-09-19 2025-03-04 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のためのカーボネート含有脂質化合物及び組成物
JP7681617B2 (ja) 2020-04-09 2025-05-22 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質ナノ粒子組成物
AR125204A1 (es) 2021-03-24 2023-06-21 Modernatx Inc Compuestos de lípidos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
AR127892A1 (es) 2021-12-10 2024-03-06 Modernatx Inc Compuestos y composiciones para la administración de agentes terapéuticos
CN116924923A (zh) 2022-04-02 2023-10-24 科镁信（上海）生物医药科技有限公司 阳离子脂质、脂质体及用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508235A (ja) 2008-11-07 2012-04-05 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
US20120295832A1 (en) 2011-05-17 2012-11-22 Arrowhead Research Corporation Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds

Also Published As

Publication number Publication date
ES2913626T3 (es) 2022-06-03
US20210161829A1 (en) 2021-06-03
SMT202200252T1 (it) 2022-07-21
EP3394030A1 (en) 2018-10-31
EP3394030B2 (en) 2025-02-12
DK3394030T3 (da) 2022-03-28
AU2021215174B2 (en) 2023-09-28
ES2913626T5 (en) 2025-05-12
WO2017112865A1 (en) 2017-06-29
US20180333366A1 (en) 2018-11-22
AU2016377681A1 (en) 2018-06-14
AU2021215174A1 (en) 2021-09-02
CY1125087T1 (el) 2023-06-09
US10799463B2 (en) 2020-10-13
US10195156B2 (en) 2019-02-05
AU2016377681B2 (en) 2021-05-13
HUE057877T2 (hu) 2022-06-28
HRP20220268T1 (hr) 2022-05-13
US20180369419A1 (en) 2018-12-27
PL3394030T3 (pl) 2022-04-11
EP3394030B1 (en) 2021-12-22
EP4036079B1 (en) 2025-11-19
EP4036079A3 (en) 2022-09-28
JP7367137B2 (ja) 2023-10-23
SI3394030T1 (sl) 2022-04-29
US12396961B2 (en) 2025-08-26
EP4036079A2 (en) 2022-08-03
LT3394030T (lt) 2022-04-11
JP2019508371A (ja) 2019-03-28
CA3007297A1 (en) 2017-06-29
RS63051B1 (sr) 2022-04-29
JP2022160523A (ja) 2022-10-19

Similar Documents

Publication Publication Date Title
JP7367137B2 (ja) 薬剤の細胞内送達のための化合物および組成物
JP7326395B2 (ja) 治療剤の細胞内送達のための化合物および組成物
US12077501B2 (en) Compounds and compositions for intracellular delivery of agents
JP7596343B2 (ja) 治療剤の細胞内送達のための化合物及び組成物
JP7410135B2 (ja) 治療薬の細胞内送達のための化合物及び組成物
HK40078722A (en) Compounds and compositions for intracellular delivery of agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220727

R150 Certificate of patent or registration of utility model

Ref document number: 7114465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250